GlassScriptPhysician profile
Sam T Rougas
NPI 1649416843
$6,338.94
in general payments reported to CMS, 2019-2025
43 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $269 · 2021: $583 · 2022: $1,414 · 2023: $1,616 · 2024: $1,267 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,225 · Education: $136 · Consulting Fee: $25.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,225.24 |
| Education | $135.75 |
| Consulting Fee | $25.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $867.82 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $522.76 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $377.90 | 2019-2024 | |
| Amgen INC. | $351.18 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $316.72 | 2020-2024 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.63 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $316.44 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Janssen Pharmaceuticals, INC | $306.40 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $305.72 | 2022-2025 | Verquvo, Lagevrio |
| E.R. Squibb & Sons, L.L.C. | $302.48 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $290.50 | 2023-2025 | Wegovy, Ozempic |
| Kiniksa Pharmaceuticals, LTD. | $258.22 | 2021-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $251.14 | 2021-2024 | Onpattro |
| Cvrx, INC. | $236.49 | 2023 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $201.01 | 2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Rougas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.